|
1
|
Glimcher L, Shen FW and Cantor H:
Identification of a cell-surface antigen selectively expressed on
the natural killer cell. J Exp Med. 145:1–9. 1997.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cooley S, Parham P and Miller JS:
Strategies to activate NK cells to prevent relapse and induce
remission following hematopoietic stem cell transplantation. Blood.
131:1053–1062. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wu Y, Tian Z and Wei H: Developmental and
functional control of natural killer cells by cytokines. Front
Immunol. 8(930)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Crouse J, Xu HC, Lang PA and Oxenius A: NK
cells regulating T cell responses: Mechanisms and outcome. Trends
Immunol. 36:49–58. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lanier LL: Up on the tightrope: Natural
killer cell activation and inhibition. Nat Immunol. 9:495–502.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Wu J and Lanier LL: Natural killer cells
and cancer. Adv Cancer Res. 90:127–156. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chong WP, van Panhuys N, Chen J, Silver
PB, Jittayasothorn Y, Mattapallil MJ, Germain RN and Caspi RR:
NK-DC crosstalk controls the autopathogenic Th17 response through
an innate IFN-γ-IL-27 axis. J Exp Med. 212:1739–1752.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jung IH, Kim DH, Yoo DK, Baek SY, Jeong
SH, Jung DE, Park SW and Chung YY: In vivo study of natural killer
(NK) cell cytotoxicity against cholangiocarcinoma in a nude mouse
model. In Vivo. 32:771–781. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chester C, Fritsch K and Kohrt HE: Natural
killer cell immunomodulation: Targeting activating, inhibitory, and
co-stimulatory receptor signaling for cancer immunotherapy. Front
Immuno. 6(601)2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Paul S and Lal G: The molecular mechanism
of natural killer cells function and its importance in cancer
immunotherapy. Front Immunol. 8(1124)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Valiante NM, Uhrberg M, Shilling HG,
Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL
and Parham P: Functionally and structurally distinct NK cell
receptor repertoires in the peripheral blood of two human donors.
Immunity. 7:739–751. 1997.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Konjević G, Vuletić A and Mirjačić
Martinović K: Natural killer cell receptors: Alterations and
therapeutic targeting in malignancies. Immunol Res. 64:25–35.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yokoyama WM and Kim S: How do natural
killer cells find self to achieve tolerance? Immunity. 24:249–257.
2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Carotta S: Targeting NK cells for
anticancer immunotherapy: Clinical and preclinical approaches.
Front Immunol. 7(152)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kochenderfer JN, Dudley ME, Feldman SA,
Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes
MS, Sherry RM, et al: B-cell depletion and remissions of malignancy
along with cytokine-associated toxicity in a clinical trial of
anti-CD19 chimeric-antigen-receptor transduced T cells. Blood.
119:2709–2720. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Porter DL, Levine BL, Kalos M, Bagg A and
June CH: Chimeric antigen receptor-modified T cells in chronic
lymphoid leukemia. N Engl J Med. 365:725–733. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Maude SL, Teachey DT, Porter DL and Grupp
SA: CD19-targeted chimeric antigen receptor T-cell therapy for
acute lymphoblastic leukemia. Blood. 125:4017–4023. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lee DW, Santomasso BD, Locke FL, Ghobadi
A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et
al: ASTCT consensus grading for cytokine release syndrome and
neurologic toxicity associated with immune effector cells. Biol
Blood Marrow Transplant. 25:625–638. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Davila ML, Riviere I, Wang X, Bartido S,
Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska
M, et al: Efficacy and toxicity management of 19-28z CAR T cell
therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.
6(224ra25)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Neelapu SS, Tummala S, Kebriaei P, Wierda
W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, et al:
Toxicity management after chimeric antigen receptor T cell therapy:
One size does not fit ‘ALL’. Nat Rev Clin Oncol.
15(218)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu
T, Yin J, You F, Zhu M, Shen W, et al: First-in-man clinical trial
of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients
with relapsed and refractory acute myeloid leukemia. Am J Cancer
Res. 8:1083–1089. 2018.PubMed/NCBI
|
|
22
|
Morgan RA, Yang JC, Kitano M, Dudley ME,
Laurencot CM and Rosenberg SA: Case report of a serious adverse
event following the administration of T cells transduced with a
chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shaffer BC, Le Luduec JB, Forlenza C,
Jakubowski AA, Perales MA, Young JW and Hsu KC: Phase II study of
haploidentical natural killer cell infusion for treatment of
relapsed or persistent myeloid malignancies following allogeneic
hematopoietic cell transplantation. Biol Blood Marrow Transplant.
22:705–709. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu E, Tong Y, Dotti G, Shaim H, Savoldo
B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, et al: Cord
blood NK cells engineered to express IL-15 and a CD19-targeted CAR
show long-term persistence and potent antitumor activity. Leukemia.
32:520–531. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li Y, Hermanson DL, Moriarity BS and
Kaufman DS: Human iPSC-derived natural killer cells engineered with
chimeric antigen receptors enhance anti-tumor activity. Cell Stem
Cell. 23:181–192.e5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Maki G, Klingemann HG, Martinson JA and
Tam YK: Factors regulating the cytotoxic activity of the human
natural killer cell line, NK-92. J Hematother Stem Cell Res.
10:369–383. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Suck G, Odendahl M, Nowakowska P, Seidl C,
Wels WS, Klingemann HG and Tonn T: NK-92: An ‘off-the-shelf
therapeutic’ for adoptive natural killer cell-based cancer
immunotherapy. Cancer Immunol Immunother. 65:485–492.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Murakami T, Nakazawa T, Natsume A,
Nishimura F, Nakamura M, Matsuda R, Omoto K, Tanaka Y, Shida Y,
Park YS, et al: Novel human NK cell line carrying CAR targeting
EGFRvIII induces antitumor effects in glioblastoma cells.
Anticancer Res. 38:5049–5056. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xiao L, Cen D, Gan H, Sun Y, Huang N,
Xiong H, Jin Q, Su L, Liu X, Wang K, et al: Adoptive transfer of
NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer
patients. Mol Ther. 27:1114–1125. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Müller N, Michen S, Tietze S, Töpfer K,
Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I and Temme A:
Engineering NK cells modified with an EGFRvIII-specific chimeric
antigen receptor to overexpress CXCR4 improves immunotherapy of
CXCL12/SDF-1α-secreting glioblastoma. J Immunother. 38:197–210.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sahm C, Schönfeld K and Wels WS:
Expression of IL-15 in NK cells results in rapid enrichment and
selective cytotoxicity of gene-modified effectors that carry a
tumor-specific antigen receptor. Cancer Immunol Immunother.
61:1451–1461. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Esser R, Müller T, Stefes D, Kloess S,
Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C,
Schönfeld K, et al: NK cells engineered to express a GD2-specific
antigen receptor display built-in ADCC-like activity against tumour
cells of neuroectodermal origin. J Cell Mol Med. 16:569–581.
2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chang YH, Connolly J, Shimasaki N, Mimura
K, Kono K and Campana D: A chimeric receptor with NKG2D specificity
enhances natural killer cell activation and killing of tumor cells.
Cancer Res. 73:1777–1786. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Becker PS, Suck G, Nowakowska P, Ullrich
E, Seifried E, Bader P, Tonn T and Seidl C: Selection and expansion
of natural killer cells for NK cell-based immunotherapy. Cancer
Immunol Immunother. 65:477–484. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li Y, Liu B, Ding S, Liu C, Chen T, Li L,
Shao Z and Fu R: Availability of NK cell expansion agent combined
with recombinant IL-2 and IL-15 stimulation on the expansion and
high-purity of NK cells in patients with immune-related
pancytopenia in vitro. Mol Med Rep. 20:4358–4366.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ojo EO, Sharma AA, Liu R, Moreton S,
Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP,
et al: Membrane bound IL-21 based NK cell feeder cells drive robust
expansion and metabolic activation of NK cells. Sci Rep.
9(14916)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kweon S, Phan MT, Chun S, Yu H, Kim J, Kim
S, Lee J, Ali AK, Lee SH, Kim SK, et al: Expansion of human NK
cells using K562 cells expressing OX40 ligand and short exposure to
IL-21. Front Immunol. 10(879)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Phan MT, Lee SH, Kim SK and Cho D:
Expansion of NK cells using genetically engineered K562 feeder
cells. Methods Mol Biol. 1441:167–174. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ferrari de Andrade L, Tay RE, Pan D, Luoma
AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ,
et al: Antibody-mediated inhibition of MICA and MICB shedding
promotes NK cell-driven tumor immunity. Science. 359:1537–1542.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu H, Wang S, Xin J, Wang J, Yao C and
Zhang Z: Role of NKG2D and its ligands in cancer immunotherapy. Am
J Cancer Res. 9:2064–2078. 2019.PubMed/NCBI
|
|
41
|
Pende D, Meazza R, Marcenaro S, Aricò M
and Bottino C: 2B4 dysfunction in XLP1 NK cells: More than
inability to control EBV infection. Clin Immunol. 204:31–36.
2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Miller JS, Soignier Y,
Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna
D, Le C, Defor TE, Burns LJ, et al: Successful adoptive transfer
and in vivo expansion of human haploidentical NK cells in patients
with cancer. Blood. 105:3051–3057. 2005.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Dunai C and Murphy WJ: NK cells for
PD-1/PD-L1 blockade immunotherapy: Pinning down the NK cell. J Clin
Invest. 128:4251–4253. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liu E, Marin D, Banerjee P, Macapinlac HA,
Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan
M, et al: Use of CAR-transduced natural killer cells in CD19
positive lymphoid tumors. N Engl J Med. 382:545–553.
2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang GP, Garrigue A, Ciuffi A, Ronen K,
Leipzig J, Berry C, Lagresle-Peyrou C, Benjelloun F,
Hacein-Bey-Abina S, Fischer A, et al: DNA bar coding and
pyrosequencing to analyze adverse events in therapeutic gene
transfer. Nucleic Acids Res. 36(e49)2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hu WS and Pathak VK: Design of retroviral
vectors and helper cells for gene therapy. Pharmacol Rev.
52:493–511. 2000.PubMed/NCBI
|
|
47
|
Hu Y, Tian ZG and Zhang C: Chimeric
antigen receptor (CAR)-transduced natural killer cells in tumor
immunotherapy. Acta Pharmacol Sin. 39:167–176. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chen X, Xu D, Zhang J and Tang J: Future
perspectives of sleeping beauty transposon system in cancer
research. EBioMedicine. 46:2–3. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chicaybam L, Abdo L, Carneiro M, Peixoto
B, Viegas M, de Sousa P, Fornazin MC, Spago MC, Albertoni
Laranjeira AB, de Campos-Lima PO, et al: CAR T cells generated
using sleeping beauty transposon vectors and expanded with an
EBV-transformed lymphoblastoid cell line display antitumor activity
in vitro and in vivo. Hum Gene Ther. 30:511–522. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hou X, Du Y, Deng Y, Wu J and Cao G:
Sleeping Beauty transposon system for genetic etiological research
and gene therapy of cancers. Cancer Biol Ther. 16:8–16.
2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ng YY, Tay JCK and Wang S: CXCR1
expression to improve anti-cancer efficacy of intravenously
injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther
Oncolytics. 16:75–85. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Fang F, Xiao W and Tian Z: NK cell-based
immunotherapy for cancer. Semin Immunol. 31:37–54. 2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lapteva N, Durett AG, Sun J, Rollins LA,
Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, et al:
Large-scale ex vivo expansion and characterization of natural
killer cells for clinical applications. Cytotherapy. 14:1131–1143.
2012.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Shevtsov M, Pitkin E, Ischenko A, Stangl
S, Khachatryan W, Galibin O, Edmond S, Lobinger D and Multhoff G:
Ex vivo Hsp70-activated NK cells in combination with PD-1
inhibition significantly increase overall survival in preclinical
models of glioblastoma and lung cancer. Front Immunol.
10(454)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Makowska A, Braunschweig T, Denecke B,
Shen L, Baloche V, Busson P and Kontny U: Interferon β and
anti-PD-1/PD-L1 checkpoint blockade cooperate in NK cell-mediated
killing of nasopharyngeal carcinoma cells. Transl Oncol.
12:1237–1256. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Perez-Santos M, Guerrero-González T,
Gómez-Conde E, Cebada J, Flores A and Villa-Ruano N: Treatment of
cancer with an anti-KIR antibody: A patent evaluation of US9879082
and US2018208652. Expert Opin Ther Pat. 30:159–162. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zhang X, Wang D, Li Z, Jiao D, Jin L, Cong
J, Zheng X and Xu L: Low-dose gemcitabine treatment enhances
immunogenicity and natural killer cell-driven tumor immunity in
lung cancer. Front Immunol. 11(331)2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Issels RD, Lindner LH, von
Bergwelt-Baildon M, Lang P, Rischpler C, Diem H, Mosetter B, Eckl
J, Schendel DJ, Salat C, et al: Systemic antitumor effect by
regional hyperthermia combined with low-dose chemotherapy and
immunologic correlates in an adolescent patient with
rhabdomyosarcoma-a case report. Int J Hyperthermia. 37:55–65.
2020.PubMed/NCBI View Article : Google Scholar
|
